Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ball, W. S.
Right arrow Articles by Altman, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ball, W. S., Jr
Right arrow Articles by Altman, N. R.

Radiology, Vol 186, 769-774, Copyright © 1993 by Radiological Society of North America


ARTICLES

Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease

WS Ball Jr, SN Nadel, RA Zimmerman, SE Byrd, RB Dietrich, EC Prenger, BP Drayer, MD Nelson Jr, FW Morgan and NR Altman
Department of Diagnostic Radiology, Children's Hospital Medical Center, Cincinnati, OH 45229-2899.

A phase III open-label clinical trial was conducted at 11 institutions to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. One hundred three children were included in the safety analysis; 92 were evaluated for efficacy (76 intracranial and 16 spinal examinations). Three adverse events were reported in two children. All adverse events were considered minor and resolved spontaneously without treatment or sequelae. In a comparison of enhanced T1-weighted magnetic resonance images with unenhanced T1- and T2-weighted images, enhancement of disease was noted in 70% of the intracranial and 38% of the spinal examinations. Additional diagnostic information was reported in 82% of the postcontrast intracranial examinations and 62% of the spinal examinations. Use of this additional information contributed to a potential modification of patient diagnosis in 48% of intracranial and 20% of spinal cases with additional information. These results indicate excellent safety and efficacy for use of gadoteridol in children with suspected intracranial or spinal disease.


This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
C Lohrmann, E Foeldi, J-P Bartholomae, and M Langer
Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection
Br. J. Radiol., July 1, 2007; 80(955): 569 - 573.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
J. Breslau, J. G. Jarvik, D. R. Haynor, W. T. Longstreth Jr, D. L. Kent, and K. R. Maravilla
MR Contrast Media in Neuroimaging: A Critical Review of the Literature
AJNR Am. J. Neuroradiol., April 1, 1999; 20(4): 670 - 675.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1993 by the Radiological Society of North America.